Beijing, March 3 (ZXS) -- According to the website of China's National Medical Security Administration on March 30, the National Health Insurance Administration, the Ministry of Finance, the National Health Commission, and the National Disease Control and Prevention recently issued a notice on further improving the protection of medical expenses for new crown patients, requiring that the new crown special protection policies such as full coverage of inpatient expenses and special outpatient protection be converted into conventional medical security policies.

Since China implemented the "Class B tube" for new crown virus infection on January 1 this year, the National Health Insurance Administration, together with relevant departments, jointly issued a notice and formulated a temporary special protection policy for the medical expenses of new crown patients. In response to a reporter's question on the 8th, the person in charge of the Department of Pharmaceutical Administration of the National Health Insurance Administration pointed out that the above policy was first implemented until March 30, 2023, which effectively guaranteed the demand for medical treatment and medicine for new crown patients, relieved the medical pressure of large hospitals, and helped the people smoothly pass the peak period of infection.

According to reports, the "Notice on Further Doing a Good Job in the Protection of Medical Expenses for New Crown Patients" issued this time clarifies the policy of guaranteeing medical expenses for new crown patients after April 4.

The notice requires that special protection policies such as full coverage of inpatient expenses and special outpatient protection be converted into conventional medical security policies, that the medical expenses of insured patients that meet the regulations and other Class B infectious diseases be subject to the same medical insurance reimbursement policy, and that medical insurance departments at all levels should promptly settle the medical expenses of eligible patients infected with new coronavirus infection.

The notice also pointed out that new crown treatment drugs that are not included in the medical insurance catalogue in the national new crown virus infection diagnosis and treatment plan can be temporarily included in the payment scope of the medical insurance fund if they are included in the category of "treatment costs are less different from similar drugs in the medical insurance catalog" in the Notice on Improving the Price Formation Mechanism of New Crown Treatment Drugs and Implementing Categorical Management.

The above-mentioned person in charge also said that at present, the latest price of deuterium remidevir hydrobromide tablets (Mindwi), Sennotevir tablets/ritonavir tablets (Synoxin), and the initial quotation of Leretvir tablets (Leruiling) are not higher than 1.8 times the maximum course of treatment cost of small molecule new crown drugs in the medical insurance catalogue (that is, 630 yuan / course), which meets the conditions of "the treatment cost of the course of treatment is less different from similar drugs in the medical insurance catalog", and will be temporarily included in the scope of medical insurance payment. Subsequently, if the price of other new crown treatment drugs meets the conditions, medical insurance will also pay temporarily according to the regulations.

The person in charge also said that in order to avoid the heavy economic burden of individual patients due to their heavier illness and higher costs, the notice specifically proposed that all localities should strengthen the monitoring of the medical expenses of new crown patients, and provide timely medical assistance to patients who meet the conditions for assistance and have a heavy personal burden. (End)

Translation

Search

copy